Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 4/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3222144 | 1.00 | CHRM2 (0.50) | CHRM2CHRM1CHRM4CHRM5CHRM3 | |
| SCHEMBL3222157 | 1.00 | CHRM2 (0.50) | CHRM2CHRM1CHRM4CHRM5CHRM3 | |
| SCHEMBL3222160 | 1.00 | CHRM2 (0.50) | CHRM2CHRM1CHRM4CHRM5CHRM3 | |
| SCHEMBL3207101 | 0.78 | CHRM2 (0.53) | CHRM2CHRM1CHRM4CHRM5CHRM3 | |
| SCHEMBL3207097 | 0.78 | CHRM2 (0.53) | CHRM2CHRM1CHRM4CHRM5CHRM3 | |
| SCHEMBL3225736 | 0.77 | CHRM2 (0.50) | CHRM2CHRM1CHRM4CHRM5CHRM3 | |
| SCHEMBL3225730 | 0.77 | CHRM2 (0.50) | CHRM2CHRM1CHRM4CHRM5CHRM3 | |
| SCHEMBL4023567 | 0.76 | CHRM2 (0.49) | CHRM2CHRM1CHRM4CHRM5CHRM3 | |
| SCHEMBL9094744 | 0.75 | CHRM1 (0.58) | CHRM2CHRM1CHRM4CHRM5CHRM3 | |
| SCHEMBL12017242 | 0.75 | CHRM1 (0.58) | CHRM2CHRM1CHRM4CHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056565-A1 | Heterocyclic Derivatives as M3 Muscarinic Receptors | ARGENTA DISCOVERY LIMITED (GB) | 2010-03-04 | — | — | US | disclosed |
| EP-2121688-A1 | HETEROCYCLIC DERIVATIVES AS M3 MUSCARINIC RECEPTORS | Argenta Discovery Ltd (GB) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008099186-A1 | HETEROCYCLIC DERIVATIVES AS M3 MUSCARINIC RECEPTORS | ARGENTA DISCOVERY LIMITED (GB) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056565-A1 | Heterocyclic Derivatives as M3 Muscarinic Receptors | CHRM2, CHRM3, CHRM1 | CHRM2 1/4885CHRM1 3/4885CHRM4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.